Medicinal Chemistry
Drug Design, Synthesis and Evaluation
Xiaohu Zhang
B.S. Peking University, 1990
Ph.D. Rutgers University-the State University of NJ, 1997

Research interests
1. Central nervous system diseases, especially Parkinson's disease, depression, and multiple sclerosis.
2. Oncology, especially embryonic pathway regulation, cancer stem cell regulation and inter-pathway interactions.
Research Support
Adenosine A2A antagonist as potential treatment for Parkinson’s disease. NNSF 2013-2017.
Smoothened antagonist as potential anti-cancer therapy.  NNSF 2015-2019.
Representative publications
1. Optimization of 6-heterocyclic-2-(1H-pyrazol-1-yl)-N-(pyridin-2-yl)pyrimidin-4-amine as potent adenosine A2A receptor antagonists for the treatment of Parkinson ’s disease. Zheng, J.; Yang, Z.; Li, X.; Li, L.; Ma, H.; Wang, M.; Zhang, H.; Zhen, X.*; Zhang, X.* ACS Chemical Neuroscience 2014, 5, 674-682.
2. Scaffold hopping approach to a new series of smoothened antagonists. Lu, W.; Geng, D.; Sun, Z.; Yang, Z.; Ma, H.; Zheng, J., Zhang, X.* Bioorg. Med. Chem. Lett. 2014, 24, 2300-2304.
3. Replacement of amide with bioisosteres led to a new series of potent adenosine A2A receptor antagonists.  Yang, Z.; Li, X.; Ma, H.; Zheng, J.; Zhen, X.; Zhang, X.* Bioorg. Med. Chem. Lett. 2014, 24, 152-155.
4. Cyclopamine, a naturally occurring alkaloid, and its analogues may find wide applications in cancer therapy.  Ma, H.; Li, H.; Zhang, X.* Curr. Top. Med. Chem. 2013, 13, 2208-2215.
5. Pyrrolopyrazines as selective spleen tyrosine kinase inhibitors.  Fernando Padilla, Niala Bhagirath, Shaoqing Chen, Eric Chiao, David Michael Goldstein, Johannes Cornelius Hermann, Jonathan Hsu, Joshua J. Kennedy-Smith, Andreas Kuglstatter, Cheng Liao, Wenjian Liu, Lee E. Lowrie, Jr., Kin-Chun Luk , Stephen M. Lynch, John Menke, Linghao Niu, Timothy D. Owens, Counde O-Yang, Aruna Railkar, Ryan C. Schoenfeld, Michelle Slade, Sandra Steiner, Yun-Chou Tan, Armando G. Villasenor, Ce Wang, Jutta Wanner, Wenwei Xie, Daigen Xu, Xiaohu Zhang, Mingyan Zhou, Matthew Charles Lucas  J. Med. Chem., 2013, 56, 1677.
6. Rational design of highly selective spleen tyrosine kinase inhibitors.  Matthew Charles Lucas, David Michael Goldstein, Johannes Cornelius Hermann, Andreas Kuglstatter, Wenjian Liu, Kin-Chun Luk , Fernando Padilla, Michelle Slade, Jutta Wanner, Wenwei Xie, Xiaohu Zhang, Cheng Liao  J. Med. Chem., 2012, 55, 10414.

Home | Introduction | Teaching | Faculty and Staff | International Collaborations | Resources | Human Resources | Contact Us
Copyright © 2014 College of Pharmaceutical Sciences, Soochow University · All Rights Reserved